Roche's Perjeta get another EU approval; CSL ready to buy Novartis vaccines; EU docs distrust pharma-made apps;

@FiercePharma: IDEXX shares climb on record diagnostics placements and Q2 earnings gain. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: As Hospira expands recall of ketorolac to 37M vials you've got to wonder what Pfizer thinks. Story | Follow @EricPFierce

@CarlyHFierce: Celgene fights for sanction on patent challenger Bass. More | Follow @CarlyHFierce

> Roche's ($RHHBY) Perjeta has won a new indication in Europe for use with Herceptin before surgery in HER2-postive breast cancer patients. Story

> A new survey of general practitioners in three European countries found that they distrust mobile apps made by drugmakers. Report

> Australia's CSL says it has the approvals to complete its buyout of Novartis ($NVS) influenza vaccine business and is working with the Swiss drugmaker to complete the deal. Story

> The FDA is warning doctors and pharmacies to be careful not to confuse Brintellix, an antidepressant, with Brilinta, a blood-thinning medication. Report

Medical Device News

@FierceMedDev: FierceDiagnostics story: Foundation Medicine trips in Q2 with sluggish test reimbursement. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: NeuWave Medical gets FDA clearance for software upgrade to its ablation system. Report | Follow @VarunSaxena2

@EmilyWFierce: It's not a good week to be a drugmaker in Romania. More from FiercePharma | Follow @EmilyWFierce

> Upstart gets $6M to back the first FDA-cleared, OTC conception assistance device. Story

> Lombard Medical gains a second stent graft for aneurysm repair via $50M acquisition. Article

> CMS expands Medicare coverage of speech-generating devices. Report

Biotech News

@FierceBiotech: ICYMI yesterday: Failed Alzheimer's drug wins $117M in vTv's IPO. Article | Follow @FierceBiotech

@JohnCFierce: 125 ex-$GSK R&D staffers in RTP face the ax--again (Great industry. Where else can you get fired twice in 8 months?) News | Follow @JohnCFierce

> Amgen lops another 10% off its R&D budget amid wide cost cuts. Story

> Merck's Ebola vaccine is 100% successful in interim Phase III results. News

> AstraZeneca isn't giving up on brodalumab despite its links to suicide. Article

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.